Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
Baltimore, MD – November 12, 2009 – Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has announced that two of its studies regarding its application in oncology drug development and personalized medicine have been selected for a poster and oral presentation at the upcoming AACR-EORTC conference in Boston.
A poster will be presented by Dr. Elizabeth Bruckheimer, Champions’ Vice President for Scientific Operations, which will detail the Biomerk Tumorgraft platform and its characterization. Together the results demonstrate that by maintaining the fundamental genotypic features of the original tumor along with the stromal and cancer stem cell components, the Biomerk Tumorgraft enables identification of the most promising development path for a compound in terms of indication, drug combination, and target patient populations. The platform also has the potential to identify gene pathways of response and resistance as well as prognostic molecular biomarkers. The banking and characterization efforts are performed in collaboration with South Texas Accelerated Research Therapeutics (START).
“The predictive power of the Biomerk Tumorgraft platform is very exciting,” said Dr. Bruckheimer. “Application of our models to translational drug development is demonstrating great promise in streamlining the development path of our biotech and pharma partners by giving them a more focused, accelerated and higher probability translational path in clinical trials. Additionally, we are using our platform to build our own oncology pipeline which we expect to yield improved clinical development success rates. We believe that this platform will continue to change the way in which oncology drugs are developed, and oncology patients are treated.”
In collaboration, Dr. Manuel Hidalgo, Professor of Oncology at the Universidad CEU San Pablo, Director of the Centro Integral Oncologia “Clara Campal” and Director of the Clinical Research Program at CNIO all in Madrid, Spain and Champions’ Chief Scientist will present data regarding prolonged clinical responses from Tumorgraft recommended treatments in patients with refractory advanced cancer, and the ability of the Tumorgraft platform to discover novel predictive biomarkers. He will show the correlation between Tumorgraft response in mice and clinical activity in patients, demonstrating a perfect correlation of sensitivity and response.
- From Mice to Men: Guiding Cancer Treatment through Personalized Tumorgraft Models Results in Prolonged Clinical Responses in Patients with Refractory Advanced Cancers and Discovery of Novel Predictive Biomarkers will be presented on Tuesday November 17th from 4:30 – 5:30 PM during the Proffered Paper Session.
- Establishment and Characterization of Primary Human Biomerk Tumorgraft Models: Application to Oncology Drug Development will be presented on Monday November 16th from 12:30 – 2:30 PM and 5:30 – 7:30 PM during the poster session (Abstract #A25).
For more information regarding Champions Biotechnology’s growing business and recent news, please visit www.championsbiotechnology.com.